

Appointment of Chief Executive Officer

The Board of PharmX Technologies Limited (**PharmX or the Company**) (ASX: PHX) is pleased to announce the appointment of Tom Culver as CEO effective 20th November 2023.

Tom joins PharmX with an extensive background in leading innovative technology companies, driving sales and implementing growth strategies. He has over 20 years of experience as a founder and business owner, as well as in senior leadership roles in organisations across the public and private sectors in both B2B and consumer focused enterprises.

His appointment comes as PharmX is poised for growth following significant recent investment in its EDI gateway and Marketplace capabilities. His technology, growth and leadership experience will be vital as the company focuses on revenue growth, delivering exceptional customer engagement, and raising its profile with enterprise providers and pharmacists across Australia and New Zealand.

Tom said:

"I am excited to have the opportunity to lead PharmX, a Company with an impressive legacy and fantastic community as we embark on the next chapter of growth."

"The prospect of leading a company focused on solving real customer problems for an industry that is evolving with the changing regulatory, consumer and technology trends is an incredibly exciting challenge."

Nick England will revert to his role as non-executive Chairman after a brief transition period.

Nick commented:

"The Board is delighted to have appointed a candidate of Tom's calibre and skillset to drive growth and capitalise on the repositioning of the business that has taken place over the last two years."

- ENDS -

This announcement is authorised for release by the Board of PharmX Technologies Limited.

For further information contact:

Nick England, Executive Chairman
Nick.England@pharmx.com.au

Appendix

Summary of CEO employment terms

1. Annual salary of \$300k excluding superannuation.
2. Short term incentive of 30% of annual salary based on achievement of financial goals.
3. Issue of 10m performance rights as part of the Company's Long Term Incentive Plan.